Cheng, Z.; Yu, F.; Chen, R.; Cui, L.; Chen, Y.; Deng, C.; Shi, Y.; Tan, H.
Treatment, Prognostic Markers, and Survival in Thymic Neuroendocrine Tumors, with Special Reference to Temozolomide-Based Chemotherapy. Cancers 2024, 16, 2502.
https://doi.org/10.3390/cancers16142502
AMA Style
Cheng Z, Yu F, Chen R, Cui L, Chen Y, Deng C, Shi Y, Tan H.
Treatment, Prognostic Markers, and Survival in Thymic Neuroendocrine Tumors, with Special Reference to Temozolomide-Based Chemotherapy. Cancers. 2024; 16(14):2502.
https://doi.org/10.3390/cancers16142502
Chicago/Turabian Style
Cheng, Zixuan, Fuhuan Yu, Ruao Chen, Lingjun Cui, Yingying Chen, Chao Deng, Yanfen Shi, and Huangying Tan.
2024. "Treatment, Prognostic Markers, and Survival in Thymic Neuroendocrine Tumors, with Special Reference to Temozolomide-Based Chemotherapy" Cancers 16, no. 14: 2502.
https://doi.org/10.3390/cancers16142502
APA Style
Cheng, Z., Yu, F., Chen, R., Cui, L., Chen, Y., Deng, C., Shi, Y., & Tan, H.
(2024). Treatment, Prognostic Markers, and Survival in Thymic Neuroendocrine Tumors, with Special Reference to Temozolomide-Based Chemotherapy. Cancers, 16(14), 2502.
https://doi.org/10.3390/cancers16142502